Resource impact statement

Cancer Drugs Fund technology

NICE has recommended nivolumab for use within the Cancer Drugs Fund as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease.

Nivolumab will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Bristol–Myers Squibb have a commercial access agreement that makes nivolumab available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of nivolumab will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires (December 2020), or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) – a new deal for patients, taxpayers and industry.

It is estimated that around 1,400 people per year with stage III melanoma with lymph node involvement or metastatic disease who have had complete resection are eligible for treatment with nivolumab.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 23 January 2019